about
Immunogenicity and cross-reactivity of 2009-2010 inactivated seasonal influenza vaccine in US adults and elderlyUse of licensed vaccines for active immunization of the immunocompromised hostPhase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteersAssessing the role of basic control measures, antivirals and vaccine in curtailing pandemic influenza: scenarios for the US, UK and the NetherlandsInfluenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza VaccinesH5N1 vaccines in humansInfluenza vaccination accelerates recovery of ferrets from lymphopeniaA history of influenzaSeroprevalence of pandemic influenza H1N1 in Ontario from January 2009-May 2010Model answers or trivial pursuits? The role of mathematical models in influenza pandemic preparedness planningImmunologic consequences of chemotherapy for ovarian cancer: impaired responses to the influenza vaccineImmunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (OptafluĀ®): an open label, uncontrolled study.Seroprevalence of antibody to influenza A(H1N1)pdm09 attributed to vaccination or infection, before and after the second (2010) pandemic wave in Australia.Low seroconversion after one dose of AS03-adjuvanted H1N1 pandemic influenza vaccine in solid-organ transplant recipientsCellular and humoral cross-immunity against two H3N2v influenza strains in presumably unexposed healthy and HIV-infected subjects.Hemagglutination inhibiting antibodies and protection against seasonal and pandemic influenza infectionPolymerase discordance in novel swine influenza H3N2v constellations is tolerated in swine but not human respiratory epithelial cellsSingle dose vaccination of the ASO3-adjuvanted A(H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strainsCompetitive detection of influenza neutralizing antibodies using a novel bivalent fluorescence-based microneutralization assay (BiFMA).Incorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challengeCross-neutralisation of antibodies elicited by an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains.Evolution of the M gene of the influenza A virus in different host species: large-scale sequence analysis.Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virusDifferential Immune Profiles in Two Pandemic Influenza A(H1N1)pdm09 Virus Waves at Pandemic Epicenter.Prevalence, genetics, and transmissibility in ferrets of Eurasian avian-like H1N1 swine influenza viruses.A cationic liposome-DNA complexes adjuvant (JVRS-100) enhances the immunogenicity and cross-protective efficacy of pre-pandemic influenza A (H5N1) vaccine in ferrets.Flexible label-free quantitative assay for antibodies to influenza virus hemagglutininsSeasonal Influenza Vaccination of Children Induces Humoral and Cell-Mediated Immunity Beyond the Current Season: Cross-reactivity With Past and Future Strains.Estimated cumulative incidence of pandemic (H1N1) influenza among pregnant women during the first wave of the 2009 pandemic.Prevalence of seroprotection against the pandemic (H1N1) virus after the 2009 pandemic.Risk factors and immunity in a nationally representative population following the 2009 influenza A(H1N1) pandemicImmuno-epidemiologic correlates of pandemic H1N1 surveillance observations: higher antibody and lower cell-mediated immune responses with advanced age.Programming the magnitude and persistence of antibody responses with innate immunity.Differences in antibody responses of individuals with natural infection and those vaccinated against pandemic H1N1 2009 influenza.Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.Serologic survey of the pandemic H1N1 2009 virus in Guangdong Province, China: a cross sectional study.DNA vaccination elicits protective immune responses against pandemic and classic swine influenza viruses in pigs.Revisiting the 1976 "swine flu" vaccine clinical trials: cross-reactive hemagglutinin and neuraminidase antibodies and their role in protection against the 2009 H1N1 pandemic virus in mice.Evaluation of the seroprevalence of influenza A(H1N1) 2009 on a university campus: a cross-sectional study.Cumulative incidence of pandemic influenza A (H1N1) 2009 by a community-based serological cohort study in Selenghe Province, Mongolia
P2860
Q21560857-0BBE909E-F2B5-4840-A14D-F2B6E905B3CCQ24533456-A3F297D8-73CA-4BA4-B4F2-406EB6054F8EQ24545856-893AB2C2-9FA5-4A93-A6C0-2E2FD7785660Q24645393-110DDCF3-C30F-41BA-8A3C-1B459B1F0188Q26783844-831F0D87-EA74-456F-AE1F-86FB6EE21A7AQ27000896-AFDE15D2-32D2-4194-919B-7D8F38ED067AQ27321447-2658B706-7A8D-417C-85C8-A9C114D97990Q28189170-69CC96C5-72F4-49CC-8ACC-2E67459037B7Q28742786-202CEF3D-6754-46B9-9728-38CE9B1C9A31Q30230076-C1FF20D9-E2CB-45A7-8572-BE42FF95450CQ30353632-CC677BE7-C066-4E0B-AFC9-34E494B0375DQ30355688-298C9680-00B3-4093-888F-91BBED5DC75EQ30357438-08CD8B46-E9A9-407F-BC6B-ABED9AE46BCEQ30357871-67FA95DC-0433-4548-8052-49DFAF48C0AEQ30366119-52EB3C90-0ECD-410E-9910-510BAD556DEFQ30366832-5CC9FC2B-623A-42BA-8AD7-3F2D732CE0C6Q30367947-8C725FFC-E580-4DB2-9445-3DD04E1A64C1Q30374968-23220E83-F67D-4739-BD07-3F35DD34FB75Q30375314-D042DFCE-CB5C-466A-9DC8-E11047C0246DQ30376482-8A5BBFF0-4EDB-4252-8E16-7C9DAD8C7508Q30377224-0FD446F8-E737-4ACB-83D5-DA6D60669BFDQ30377641-3D8B97CC-7275-442A-8C44-C57B7D83076FQ30379914-E94DD9AD-BD0F-4452-BBDC-4337C2AC356EQ30382796-DB4E28A6-B442-4442-AF29-DC5676A2A147Q30382958-43C1B096-6D17-4464-B673-D5C384BFC018Q30385570-EA573BD2-01F7-4F6E-B975-E0CBE4F64151Q30391853-32D19800-4B71-46D7-A1EE-5D33974C38D3Q30392333-B15F31E4-ABF0-44D2-A6AB-1ED6FAC25CBDQ30393388-6AC32EC0-2ADB-4066-B345-F750C59523D2Q30394995-F5AD4887-368B-4DF9-B6F5-A8F481B6570EQ30395289-134555F7-0349-4729-9F43-BD30207BB5DCQ30399272-372B873A-3FFB-4561-9D10-42F69FAEF55CQ30400144-FCC56F7B-E780-4F4D-8D4E-AB13751B6E87Q30400817-04382F67-A44E-43B8-91EF-9DBCC0845A5BQ30402500-F39C6031-2DFF-4C22-9E4A-02440B5E8DB9Q30406154-59D17CF9-4B8F-45D6-9F6C-D16BEEC8C339Q30407081-99DF1B00-39DC-41DE-A804-E808CEB8C72CQ30407834-1E034BE4-DBC6-4344-8C96-3CCDF67F76DAQ30410600-8B1A9C76-02E7-4901-896F-2436AD456DECQ30413007-553E9599-DD37-46E6-9C68-A93FB8084C74
P2860
description
1979 nĆ® lÅ«n-bĆ»n
@nan
1979幓ć®č«ę
@ja
1979幓č«ę
@yue
1979幓č«ę
@zh-hant
1979幓č«ę
@zh-hk
1979幓č«ę
@zh-mo
1979幓č«ę
@zh-tw
1979幓č®ŗę
@wuu
1979幓č®ŗę
@zh
1979幓č®ŗę
@zh-cn
name
Determinants of immunity to influenza infection in man.
@en
Determinants of immunity to influenza infection in man.
@nl
type
label
Determinants of immunity to influenza infection in man.
@en
Determinants of immunity to influenza infection in man.
@nl
prefLabel
Determinants of immunity to influenza infection in man.
@en
Determinants of immunity to influenza infection in man.
@nl
P1476
Determinants of immunity to influenza infection in man.
@en
P2093
P356
10.1093/OXFORDJOURNALS.BMB.A071545
P577
1979-01-01T00:00:00Z